Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (September 2023)
15 slides from Bio-gene Technology's investor presentation, Sep 1, 2023
Slide 1: Placement to sophisticated and professional investors and SPP
ASX ANNOUNCEMENT 1 SEPTEMBER 2023 Placement to sophisticated and professional investors and SPP Bio-Gene Technology Limited (ASX: BGT, Bio-Gene or the Company), an agtech development company enabling the next generation of novel insecticides to address insecticide resistance, today announced that it
Slide 2: About Bio-Gene Technology Limited
About Bio-Gene Technology Limited Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as
Slide 3: Placement and Share Purchase Plan
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE TECHNOLOGY LIMITED SEPTEMBER 2023 Placement and Share Purchase Plan
Slide 4: Disclaimer
DISCLAIMER This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation
Slide 5: Capital Raise: Key Information & Dates
CAPITAL RAISE: KEY INFORMATION & DATES • Placement: • Share Purchase Plan (SPP): • Open to sophisticated and professional investors • Open to all eligible shareholders • Target raise: $2.5 million • Price: 8.4 cents per share - ability to accept oversubscriptions (8% discount to 30 day VWAP*) • Pric
Slide 6: Key Initiatives to Be Funded by This Capital Raise
KEY INITIATIVES TO BE FUNDED BY THIS CAPITAL RAISE Following the strong developments over the past 9 months: Active Ingredient registration studies: $2.0M • Including pivotal toxicology studies for Flavocide® • Supporting our commitments to commercial partners, maintain our timeline of registrations
Slide 7: Key Commercial Achievements - FY23
KEY COMMERCIAL ACHIEVEMENTS - FY23 Strong commercial partnerships and third-party validation Partnership Advancement Made Value Add STK fully funding multi-million dollar Qcide® registration cost Completion of STK agreement for Qcide® BGT retains full commercial flexibility Enables BGT to work
Slide 8: Key Commercial Achievements - FY23
KEY COMMERCIAL ACHIEVEMENTS - FY23 Strong progress towards our key target markets: FY23 Key Achievements US$31.1 billion Addressable Market STK Clarke Synergy GRDC Patent Agreement Extension Results Support Protection US$1Bn Stored Grain US$4Bn Public Health Consumer Key Achievements subsequent to y
Slide 9: Other Key Operational Achievements
OTHER KEY OPERATIONAL ACHIEVEMENTS Synergy data: • Significant opportunity to reduce insecticide load, address resistance, reduce cost & support post-patent strategies for partners • Opens broader market possibilities CDC funded program on ticks • US Government funded - to demonstrate fit with tick
Slide 10: A New Leadership Team - For Next Stage of Growth
A NEW LEADERSHIP TEAM - FOR NEXT STAGE OF GROWTH • Alex Ding - appointed as Chair upon retirement of Robert Klupacs • Recognised expert in mergers & acquisitions, capital markets, general corporate & governance law • Tim Grogan - appointed as new MD & CEO • Successful track record of delivering grow
Slide 11: BGT - Key Financial Metrics
BGT - KEY FINANCIAL METRICS AUD ($‘000) FY22 FY23 • FY23 Commentary: Revenue 446 149 • Revenue includes milestone payments $150k Other income 493 532 • Other income includes R&D refund ~$440k Reported Net Loss (2,914) (3,096) per year FY22 FY23 • Net Cash Used in Operations included: Net Cash Used i
Slide 12: Supporting Background
xe) Cc D ie) wa 1o%) ~< U ig) aa) eX) Cc p as e) jos jos D Y)
Slide 13: Global Challenges and Resistant Pest Control
GLOBAL CHALLENGES AND RESISTANT PEST CONTROL Food Security & Public Health • Growing population = more food “Without Crop Protection, crop • Climate change = more mosquitos losses would double each year” CropLife Financial Impact • Production lost to pests = higher costs, lost income “No new public
Slide 14: Bio-Gene's Chemistry Is a Step-Change for Resistant Pest Control
BIO-GENE'S CHEMISTRY IS A STEP-CHANGE FOR RESISTANT PEST CONTROL • Novel Mode of Action (MoA) • Last new MoA commercialised in 2008, with current sales of US$2.3bn • Naturally derived and safe chemistry • Efficacy across a number of target pests Qcide® Flavocide® • Addresses multiple market segments
Slide 15: Bio-Gene Technology Limited
ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES BIO-GENE TECHNOLOGY LIMITED Contacts: Tim Grogan MD & CEO timg@bio-gene.com.au Rod Valencia CFO, Company Secretary & Investor Relations rodv@bio-gene.com.au www.bio-gene.com.au
Bio-gene Technology — Investor Presentation (September 2023) on 6ix